Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rupert Bartsch

Showing results (201-210 of 228) with videos related to

Pageof 23
Sort By:
Nature Medicine|August 8, 2022
Trastuzumab deruxtecan in HER2-positive breast cancer with brain metastases: a single-arm, phase 2 trialRupert Bartsch, Anna Sophie Berghoff, Julia Furtner, et al.
Cancer Medicine|March 22, 2022
The cancer survival index-A prognostic score integrating psychosocial and biological factors in patients diagnosed with cancer or haematologic malignanciesAlexander Gaiger, Simone Lubowitzki, Katharina Krammer, et al.
NPJ Breast Cancer|December 20, 2025
Novel treatment strategies and key research priorities for patients with breast cancer and central nervous system (CNS) metastasesKatarzyna J Jerzak, Evangelia D Razis, Elisa Agostinetto, et al.
The Oncologist|June 9, 2021
Clinicopathologic and Genomic Landscape of Breast Carcinoma Brain MetastasesRichard S P Huang, James Haberberger, Kimberly McGregor, et al.
The Lancet. Oncology|October 30, 2025
Patritumab deruxtecan (HER3-DXd) in patients with active brain metastases of breast cancer (TUXEDO-3): a multicentre, single-arm, phase 2 trialRupert Bartsch, Maximilian Marhold, Javier Garde-Noguera, et al.
Breast (Edinburgh, Scotland)|June 29, 2026
Tucatinib in patients with HER2-positive advanced/metastatic breast cancer: A systematic literature review of real-world evidenceRodrigo Sanchez-Bayona, Carey Anders, Rupert Bartsch, et al.
Nature Medicine|May 30, 2025
Patritumab deruxtecan in leptomeningeal metastatic disease of solid tumors: the phase 2 TUXEDO-3 trialMatthias Preusser, Javier Garde-Noguera, Juan José García-Mosquera, et al.
British Journal of Cancer|March 25, 2021
Conventional versus reverse sequence of neoadjuvant epirubicin/cyclophosphamide and docetaxel: sequencing results from ABCSG-34Rupert Bartsch, Christian F Singer, Georg Pfeiler, et al.
ESMO Open|August 28, 2020
Oncological care organisation during COVID-19 outbreakConcetta Elisa Onesti, Hope S Rugo, Daniele Generali, et al.
European Journal of Cancer (Oxford, England : 1990)|April 24, 2020
Efficacy and safety of the therapeutic cancer vaccine tecemotide (L-BLP25) in early breast cancer: Results from a prospective, randomised, neoadjuvant phase II study (ABCSG 34)Christian F Singer, Georg Pfeiler, Michael Hubalek, et al.
Pageof 23

Showing results (201-210 of 228) with videos related to

Sort By:
Pageof 23
Nature Medicine|August 8, 2022
Trastuzumab deruxtecan in HER2-positive breast cancer with brain metastases: a single-arm, phase 2 trialRupert Bartsch, Anna Sophie Berghoff, Julia Furtner, et al.
Cancer Medicine|March 22, 2022
The cancer survival index-A prognostic score integrating psychosocial and biological factors in patients diagnosed with cancer or haematologic malignanciesAlexander Gaiger, Simone Lubowitzki, Katharina Krammer, et al.
NPJ Breast Cancer|December 20, 2025
Novel treatment strategies and key research priorities for patients with breast cancer and central nervous system (CNS) metastasesKatarzyna J Jerzak, Evangelia D Razis, Elisa Agostinetto, et al.
The Oncologist|June 9, 2021
Clinicopathologic and Genomic Landscape of Breast Carcinoma Brain MetastasesRichard S P Huang, James Haberberger, Kimberly McGregor, et al.
The Lancet. Oncology|October 30, 2025
Patritumab deruxtecan (HER3-DXd) in patients with active brain metastases of breast cancer (TUXEDO-3): a multicentre, single-arm, phase 2 trialRupert Bartsch, Maximilian Marhold, Javier Garde-Noguera, et al.
Breast (Edinburgh, Scotland)|June 29, 2026
Tucatinib in patients with HER2-positive advanced/metastatic breast cancer: A systematic literature review of real-world evidenceRodrigo Sanchez-Bayona, Carey Anders, Rupert Bartsch, et al.
Nature Medicine|May 30, 2025
Patritumab deruxtecan in leptomeningeal metastatic disease of solid tumors: the phase 2 TUXEDO-3 trialMatthias Preusser, Javier Garde-Noguera, Juan José García-Mosquera, et al.
British Journal of Cancer|March 25, 2021
Conventional versus reverse sequence of neoadjuvant epirubicin/cyclophosphamide and docetaxel: sequencing results from ABCSG-34Rupert Bartsch, Christian F Singer, Georg Pfeiler, et al.
ESMO Open|August 28, 2020
Oncological care organisation during COVID-19 outbreakConcetta Elisa Onesti, Hope S Rugo, Daniele Generali, et al.
European Journal of Cancer (Oxford, England : 1990)|April 24, 2020
Efficacy and safety of the therapeutic cancer vaccine tecemotide (L-BLP25) in early breast cancer: Results from a prospective, randomised, neoadjuvant phase II study (ABCSG 34)Christian F Singer, Georg Pfeiler, Michael Hubalek, et al.
Pageof 23